Syndax Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2014
Net Income	-240.63	-209.36	-149.34	24.93	-77.06	-56.05	Upgrade
Depreciation & Amortization	0.89	0.75	0.45	0.46	0.52	0.45	Upgrade
Share-Based Compensation	33.61	30.95	16.02	13.32	9.06	6.01	Upgrade
Other Operating Activities	1.22	17.06	-0.81	-9.57	-3.77	-1.02	Upgrade
Operating Cash Flow	-204.92	-160.6	-133.68	29.13	-71.26	-50.61	Upgrade
Capital Expenditures	0	0	0.23	-0.13	0	0	Upgrade
Change in Investments	-1.71	117.61	-186.41	-40.74	-142.53	12.78	Upgrade
Investing Cash Flow	-1.71	117.61	-186.19	-40.87	-142.53	12.78	Upgrade
Share Issuance / Repurchase	263.83	264.13	193.25	117.89	284.69	28.57	Upgrade
Debt Issued / Paid	0	0	-21	0.58	19.73	0	Upgrade
Other Financing Activities	-	-	-	-	0	-	Upgrade
Financing Cash Flow	263.83	264.13	172.25	118.46	304.42	28.57	Upgrade
Net Cash Flow	57.2	221.14	-147.61	106.72	90.63	-9.26	Upgrade
Free Cash Flow	-204.92	-160.6	-133.45	29	-71.26	-50.61	Upgrade
Free Cash Flow Margin	-	-	-	20.76%	-4697.43%	-3336.32%	Upgrade
Free Cash Flow Per Share	-2.40	-2.28	-2.20	0.56	-1.73	-1.66	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).